Status:
COMPLETED
PPAR - Combination With Metformin
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who ...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- HbA1c \> - 7.0% and \< - 10.0 %
- Mean serum triglyceride \< - 600 mg/dL
- Body mass index \< - 41 kg/m2
- Fasting c-peptide \> - 1.0 ng/mL
Exclusion
- History of myocardial infarction (MI)
- coronary angioplasty or bypass graft(s)
- valvular disease or repair
- unstable angina pectoris
- transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months
- Congestive heart failure NYHA Class III and IV
- Uncontrolled hypertension
- History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2004
Estimated Enrollment :
534 Patients enrolled
Trial Details
Trial ID
NCT00162240
Start Date
June 1 2003
End Date
May 1 2004
Last Update
April 27 2012
Active Locations (203)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Anniston, Alabama, United States
2
Local Institution
Birmingham, Alabama, United States
3
Local Institution
Haleyville, Alabama, United States
4
Local Institution
Mobile, Alabama, United States